U.S. trial test machine that ‘reconditions’ lungs outside body

(Reuters) – A machine that ‘reconditions’ a donor’s lungs outside the body before being transplanted into a recipient is undergoing tests in the United States in the hope that it can radically improve survival rates for people with chronic respiratory diseases. The XPS, manufactured by Swedish company XVIVO Perfusion , is in clinical trials at 16 U.S. medical centers. Known as “the box,” it ventilates the lungs after removal from the donor and infuses them with a fluid mix of drugs and steroids, effectively drying them out and getting them in better shape for use in a transplant operation. The technology, which has not been used widely before, aims to increase the donor pool by reconditioning marginal lungs not suitable for transplant. “It allows the lungs to stay alive … and allows us as providers to assess the function of the organ in a unique, well-controlled environment,” said Dr. Varun Puri, an associate professor of cardiothoracic surgery at Washington University in St. Louis. The XPS, which is under test at Washington University, Duke University Medical Center, New York-Presbyterian Hospital and more than a dozen other U.S. sites, has been cleared for use in Europe and Canada and was approved for clinical trials by the U.S. Food and Drug Administration as a Humanitarian Use Device. Michele Coleman, 63, credits ‘the box’ with saving her life. A former smoker, she was diagnosed with chronic obstructive pu...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Respiratory XVIVO Perfusion Source Type: news

Related Links:

Conclusions: To our knowledge, this is the first study to report on the rates of acceptance of digital invitations to participate in a stepwise model for prevention of chronic diseases. More studies of digital invitations are needed to determine if the acceptance rates seen in this study should be expected from future studies as well. Similarly, more research is needed to determine whether a multimodal recruitment approach, including digital invitations to personal digital mailboxes will reach hard-to-reach subpopulations more effectively than digital invitations only.
Source: Journal of Medical Internet Research - Category: General Medicine Authors: Source Type: research
Publication date: Available online 19 January 2019Source: Journal of Alloys and CompoundsAuthor(s): Chuan-Che Hsu, Chak-Ming Liu, Zong-You Lin, Wen-Chin LinAbstractCoPd alloy nanostructures and thin films were deposited on MoS2 flakes through e-beam evaporation at a high temperature (HT) (500 K) and at room temperature (RT) (300 K). In HT growth, CoPd nanoparticles assembled at the edge of the MoS2 flake. The nanoparticles formed parallel chains at the edge of each layer in multilayered MoS2. As indicated by the quenched photoluminescence, HT deposition resulted in a flat CoPd coverage with a roughness of ≤±0...
Source: Journal of Alloys and Compounds - Category: Chemistry Source Type: research
Conclusions: Comprehensive screening for regulatory variants near FAM13A identified the presence of extensive functional regulatory variation within a 250kb window of FAM13A in HBECs. Focused functional evaluation of the COPD-associated functional variants in LD with the two independent association signals in this region prioritized the common variant rs2013701, for which multiple parallel lines of functional evidence confirm allelic effects on FAM13A regulation.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Other Homo sapiens Source Type: research
ConclusionIn ‐hospital mortality remained stable and LOS decreased over time, despite greater comorbidity and more severe AHRF in COPD patients treated for the first time with ward‐based NIV.This article is protected by copyright. All rights reserved.
Source: The Clinical Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Brief Report Source Type: research
Authors: Șerban RC, Șuș I, Lakatos EK, Demjen Z, Ceamburu A, Fișcă PC, Somkereki C, Hadadi L, Scridon A Abstract BACKGROUND: Atrial fibrillation (AF) often complicates ST-segment elevation myocardial infarction (STEMI). Predictors of AF in this setting include factors related to the acute phase of STEMI and pre-existing conditions. More recently, novel AF predictors have been identified in the general population. We aimed to assess the ability of such novel factors to predict STEMI-related AF. METHODS: Data were collected from STEMI patients treated by primary PCI. Factors related to the acute phase of STE...
Source: Acta Cardiologica - Category: Cardiology Tags: Acta Cardiol Source Type: research
Authors: Horodinschi RN, Bratu OG, Dediu GN, Pantea Stoian A, Motofei I, Diaconu CC Abstract Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are important causes of morbidity and mortality worldwide. The association between the two conditions have significant systemic effects and a chronic, progressive evolution, affecting exercise tolerance and quality of life. The diseases share common risk factors, such as smoking, advanced age, and low-grade systemic inflammation. The majority of symptoms and physical signs, such as dyspnoea, orthopnea, nocturnal cough, exercise intolerance, muscle weakness ...
Source: Acta Cardiologica - Category: Cardiology Tags: Acta Cardiol Source Type: research
ConclusionsCOPD in comorbidity of depression could induce spatial memory deficit in old rats. The mechanisms might be related to the overloaded and free radical metabolic imbalance. These results suggest a potential therapeutic target for comorbidity of COPD and depression in geriatric patients.
Source: Chinese Medical Sciences Journal - Category: General Medicine Source Type: research
Condition:   COPD Interventions:   Drug: QAW039;   Drug: Placebo Sponsor:   Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Chronic Respiratory Failure;   COPD;   Obesity Hypoventilation Syndrome Intervention:   Diagnostic Test: Microbiological sampling Sponsors:   University Hospital, Rouen;   ADIR Association Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COPD Interventions:   Drug: QAW039;   Drug: Placebo Sponsor:   Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cardiology | Chronic Obstructive Pulmonary | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Heart | Hospitals | Lung Transplant | Medical Devices | Perfusion | Respiratory Medicine | Smokers | Statistics | Transplant Surgery | Transplants | Washington University